Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 Feb 15

PMID 35164092

Authors

Tasia Amelia

Rahmana Emran Kartasasmita

Tomohiko Ohwada

Daryono Hadi Tjahjono

Affiliations

Soon will be listed here.

Abstract

Lung cancer has a high prevalence, with a growing number of new cases and mortality every year. Furthermore, the survival rate of patients with non-small-cell lung carcinoma (NSCLC) is still quite low in the majority of cases. Despite the use of conventional therapy such as tyrosine kinase inhibitor for Epidermal Growth Factor Receptor (EGFR), which is highly expressed in most NSCLC cases, there was still no substantial improvement in patient survival. This is due to the drug's ineffectiveness and high rate of resistance among individuals with mutant EGFR. Therefore, the development of new inhibitors is urgently needed. Understanding the EGFR structure, including its kinase domain and other parts of the protein, and its activation mechanism can accelerate the discovery of novel compounds targeting this protein. This study described the structure of the extracellular, transmembrane, and intracellular domains of EGFR. This was carried out along with identifying the binding pose of commercially available inhibitors in the ATP-binding and allosteric sites, thereby clarifying the research gaps that can be filled. The binding mechanism of inhibitors that have been used clinically was also explained, thereby aiding the structure-based development of new drugs.

Citing Articles

Exploring CAR-PBMCs: A Novel Strategy Against EGFR-Positive Tumor Cells.

Tirziu A, Gavriliuc O, Bojin M, Paunescu V Biomedicines. 2025; 13(2).

PMID: 40002679 PMC: 11853248. DOI: 10.3390/biomedicines13020264.

Discovery of new benzothiazole-1,2,3-triazole hybrid-based hydrazone/thiosemicarbazone derivatives as potent EGFR inhibitors with cytotoxicity against cancer.

Aljuhani A, Nafie M, Albujuq N, Alsehli M, Bardaweel S, Darwish K RSC Adv. 2025; 15(5):3570-3591.

PMID: 39906636 PMC: 11792500. DOI: 10.1039/d4ra07540d.

[A Case Report of EGFR-TKIs Resistant Secondary MET Gene Amplified  Lung Squamous Cell Carcinoma and Literature Review].

Liu Y, Chen P, Liu X Zhongguo Fei Ai Za Zhi. 2025; 27(11):878-884.

PMID: 39800484 PMC: 11732385. DOI: 10.3779/j.issn.1009-3419.2024.106.32.

Dysregulated Signaling Pathways in Canine Mammary Tumor and Human Triple Negative Breast Cancer: Advances and Potential Therapeutic Targets.

Mei C, Liu Y, Liu Z, Zhi Y, Jiang Z, Lyu X Int J Mol Sci. 2025; 26(1.

PMID: 39796003 PMC: 11720488. DOI: 10.3390/ijms26010145.

Diverse perspectives on proteomic posttranslational modifications to address EGFR-TKI resistance in non-small cell lung cancer.

Ma Y, Zhang F, Li J, Li J, Li Y Front Cell Dev Biol. 2025; 12():1436033.

PMID: 39777265 PMC: 11703921. DOI: 10.3389/fcell.2024.1436033.

References

Fan W, Shiao M, Hui R, Su S, Wang C, Chang Y . HLA Association with Drug-Induced Adverse Reactions. J Immunol Res. 2018; 2017:3186328. PMC: 5733150. DOI: 10.1155/2017/3186328. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Al Olayan A, Al Hussaini H, Jazieh A . The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer. J Infect Public Health. 2012; 5 Suppl 1:S50-60. DOI: 10.1016/j.jiph.2012.09.004. View

Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K . The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6):2070-5. PMC: 2538882. DOI: 10.1073/pnas.0709662105. View

Mok T, Cheng Y, Zhou X, Lee K, Nakagawa K, Niho S . Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol. 2018; 36(22):2244-2250. DOI: 10.1200/JCO.2018.78.7994. View

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

Bean J, Riely G, Balak M, Marks J, Ladanyi M, Miller V . Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res. 2008; 14(22):7519-25. PMC: 2596620. DOI: 10.1158/1078-0432.CCR-08-0151. View

Yosaatmadja Y, Silva S, Dickson J, Patterson A, Smaill J, Flanagan J . Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. J Struct Biol. 2015; 192(3):539-544. DOI: 10.1016/j.jsb.2015.10.018. View

Abdallah S, Hirsh V . Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in activating mutation-positive advanced non-small-cell lung cancer. Curr Oncol. 2018; 25(Suppl 1):S9-S17. PMC: 6001770. DOI: 10.3747/co.25.3732. View

10.

Canagarajah B, Khokhlatchev A, Cobb M, Goldsmith E . Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell. 1997; 90(5):859-69. DOI: 10.1016/s0092-8674(00)80351-7. View

11.

Cheng H, Nair S, Murray B, Almaden C, Bailey S, Baxi S . Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR.... J Med Chem. 2016; 59(5):2005-24. DOI: 10.1021/acs.jmedchem.5b01633. View

12.

Landau M, Fleishman S, Ben-Tal N . A putative mechanism for downregulation of the catalytic activity of the EGF receptor via direct contact between its kinase and C-terminal domains. Structure. 2004; 12(12):2265-75. DOI: 10.1016/j.str.2004.10.006. View

13.

Jura N, Endres N, Engel K, Deindl S, Das R, Lamers M . Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell. 2009; 137(7):1293-307. PMC: 2814540. DOI: 10.1016/j.cell.2009.04.025. View

14.

Hubbard P, Moody C, Murali R . Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities. Front Physiol. 2015; 5:478. PMC: 4267178. DOI: 10.3389/fphys.2014.00478. View

15.

Haley J, Hsuan J, Waterfield M . Analysis of mammalian fibroblast transformation by normal and mutated human EGF receptors. Oncogene. 1989; 4(3):273-83. View

16.

Chang A, Parikh P, Thongprasert S, Tan E, Perng R, Ganzon D . Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol. 2007; 1(8):847-55. View

17.

Choong N, Dietrich S, Seiwert T, Tretiakova M, Nallasura V, Davies G . Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol. 2006; 3(1):50-7. DOI: 10.1038/ncponc0400. View

18.

Cross D, Ashton S, Ghiorghiu S, Eberlein C, Nebhan C, Spitzler P . AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4(9):1046-61. PMC: 4315625. DOI: 10.1158/2159-8290.CD-14-0337. View

19.

Lelimousin M, Limongelli V, Sansom M . Conformational Changes in the Epidermal Growth Factor Receptor: Role of the Transmembrane Domain Investigated by Coarse-Grained MetaDynamics Free Energy Calculations. J Am Chem Soc. 2016; 138(33):10611-22. PMC: 5010359. DOI: 10.1021/jacs.6b05602. View

20.

Avizienyte E, Ward R, Garner A . Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem J. 2008; 415(2):197-206. DOI: 10.1042/BJ20080728. View